DRP Journal

Discover Research Profit

Finance 

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Sees Buying at Lower Levels

Pete Matthews , , , ,

Biotech company Northwest Biotherapeutics (OTCMKTS:NWBO) saw its stock go on an upward move this past Friday as it ended the day with gains of as much as 6%. While the gains made by the stock were notable, it is also necessary to point out that there was no news about the company on Friday.

Market Stats

On Friday, NWBO stock went up 6.08% to $0.93 with 609K shares, compared to its average volume of 2.08 million shares. The stock moved within a range of $0.9055 – 0.9513 after opening trading at $0.9513.

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

As a matter of fact, the last time the company was in the news was back on February 17, 2022 when it made a major announcement. At the time, Northwest announced that it had started the production activities in relation to its dendritic cell cancer vaccine.

The vaccine in question is meant for compassionate use in patients and the production activities had been started at the facility that recently got the license in Swaston in United Kingdom.

In this context, it is perhaps also necessary to point out that the company actually got the MHRA license back in December last year and it had been awarded after Northwest had worked diligently towards building the Sawston plant for a period of more than two years. At this point in time, it may be a good idea for investors to keep the Northwest stock in their watch lists.

Pete Matthews

Pete attended the University of Colorado and still calls the centennial state home. He chases trout in the summer and snowboards in the winter. He is fascinated with the markets and has a strong interest in nanocap stocks and crypto currency.